相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases
Yoshiyuki Yamamoto et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips et al.
JAMA ONCOLOGY (2020)
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
Philipp Nuhn et al.
EUROPEAN UROLOGY (2019)
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study
Luca Triggiani et al.
WORLD JOURNAL OF UROLOGY (2019)
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
Daniel R. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment
C. Leigh Moyer et al.
WORLD JOURNAL OF UROLOGY (2019)
Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor
Soichiro Yoshida et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression
Yoshiyuki Miyazawa et al.
PROSTATE (2019)
Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience
Maurizio Valeriani et al.
RADIATION ONCOLOGY (2019)
Oligometastatic prostate cancer: The game is afoot
Andrea Lancia et al.
CANCER TREATMENT REVIEWS (2019)
Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Fabian Lohaus et al.
EUROPEAN UROLOGY (2019)
Oligometastatic cancer in elderly patients: the blitzkrieg radiotherapy approach: SBRT in oligometastatic elderly patients
Andrea Lancia et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2019)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Current therapeutic options in metastatic castration-resistant prostate cancer
Gianluca Ingrosso et al.
SEMINARS IN ONCOLOGY (2018)
Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience
Gianluca Ingrosso et al.
WORLD JOURNAL OF UROLOGY (2017)
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
Luca Triggiani et al.
BRITISH JOURNAL OF CANCER (2017)
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel
Francesco Ceci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)
Anthony C. Wong et al.
CANCER (2016)
PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer
Francesco Ceci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis
Piet Ost et al.
EUROPEAN UROLOGY (2016)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide
Ugo De Giorgi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer
B. Detti et al.
WORLD JOURNAL OF UROLOGY (2015)
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone
Ugo De Giorgi et al.
Oncotarget (2015)
Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Review
D. A. Loblaw et al.
CLINICAL ONCOLOGY (2013)
Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database
Emmanuel S. Antonarakis et al.
BJU INTERNATIONAL (2011)
Impact of Prostate-Specific Antigen (PSA) Nadir and Time to PSA Nadir on Disease Progression in Prostate Cancer Treated With Androgen-Deprivation Therapy
Shu-Pin Huang et al.
PROSTATE (2011)
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2010)
From Pathogenesis to Prevention of Castration Resistant Prostate Cancer
Helmut Bonkhoff et al.
PROSTATE (2010)
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2007)
Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treared with chemotherapy
Timothy J. Daskivich et al.
UROLOGY (2007)
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
Mark T. Fleming et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer
Ross C. Semeniuk et al.
UROLOGY (2006)
分享论文
